MUC1 and cancer: Thirteen patients with PD-L1 and MUC1 positive cancers, including but not limited to lung, pancreatic, ovarian and colon cancer, were enrolled in the trial and received 1 × 109 Muc1-CAR-NK-92 cells/infusion.